Earnings Reports

Found 68,568 articles

• Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update

  1/15/2021

  Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced financial results for its second quarter of fiscal year 2021, which ended November 30, 2020.

• Nuance to Release First Quarter Fiscal 2021 Results on Feb. 8, 2021

  1/15/2021

  Nuance Communications, Inc. (NASDAQ: NUAN) today announced that it will release its first quarter fiscal 2021 results on Monday, February 8, 2021 after the market close.

• Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and WebcastCall scheduled for Tuesday, February 9th at 4:30 pm Eastern Time

  1/15/2021

  Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its third fiscal quarter ended December 31, 2020 on Tuesday, Februa

• Reminder: Centene Corporation's 2020 Fourth Quarter And Full Year Financial Results Conference Call

  1/14/2021

  Centene Corporation issued a reminder that it will release its 2020 fourth quarter and full-year financial results at approximately 6 a.m. Eastern Standard Time on Tuesday, February 9th, 2021, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

• Sharps Compliance Announces Second Quarter Fiscal 2021 Conference Call and Webcast

  1/14/2021

  Sharps Compliance Corp. announced that it will release its second quarter 2021 results for the period ended December 31, 2020, before the opening of the financial markets on Thursday, January 28, 2021.

• Benchling Doubles Annual Recurring Revenue (ARR) for Fourth Straight Year Amid COVID-19 Pandemic

  1/14/2021

  The leading life sciences R&D cloud added 150 customers, including biotech innovators Gilead Sciences, Sanofi, and UCB

• Tikcro Technologies Reports Third Quarter 2020 Results

  1/14/2021

   Tikcro Technologies Ltd. (OTCQB: TIKRF), today reported its financial results for the third quarter ended September 30, 2020 . "We continue to consider businesses for a reverse merger and other corporate alternatives," said Aviv Boim , CEO of Tikcro. Financial Results for the Third Quarter Ended September 30, 2020 N

• Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2020 Revenue Results; Will Host Fourth Quarter Financial Results Conference Call on February 18, 2021

  1/14/2021

  Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter and Full-Year 2020 Revenue Results Fourth quarter 2020 revenue is expected to be in a range of $387 to $389 million, representing a decrease of 2.1% to 1.6% on a reported basis and a decrease of 1.9% to 1.4% on an

• Venus Concept Reports Preliminary Revenue Results for Fourth Quarter 2020; Introduces Fiscal Year 2021 Revenue Guidance

  1/14/2021

  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2020 and introduced revenue guidance expectations for the twelve months ended December 31, 2021. Management Commentary: “We continued to see improvements in the operating environment in our key markets in the fourth quarter as evidenced by

• Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update

  1/14/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2020 and provided a business update.

• TELA Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020

  1/14/2021

  TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2020. Preliminary Unaudited Fourth Quarter and Full Year Results: Fourth quarter revenue is expec

• Cigna Corporation's Fourth Quarter 2020 Earnings Release Details

  1/14/2021

  Global health service company Cigna Corporation (NYSE:CI) will release its fourth quarter 2020 financial results on Thursday, Feb. 4, 2021, and will host a conference call the same day.

• MustGrow Confirms Proceeds of C$1.5 Million from Warrant Exercise

  1/14/2021

  Saskatoon, Saskatchewan--(Newsfile Corp. - January 14, 2021) -  MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company", "MustGrow") is pleased to announce that it has received over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share.

• Abiomed Third Quarter Fiscal 2021 Earnings and Conference Call Notification

  1/14/2021

  Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, January 28, 2021, the Company will release financial results for the third quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, January 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to

• OpSens Announces First Quarter Fiscal 2021 Financial Results

  1/13/2021

  OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today reported its financial results for the first quarter of fiscal 2021, ended November 30, 2020 . Fir

• OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update

  1/13/2021

  Preliminary total pro-forma combined revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.3 million cash as of December 31, 2020 and total capital raised in 2020 of $35.3 million OpGen subsidiary Ares Genetics to explore multiple collaboration opportunities with several parties

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

  1/13/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

• Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

  1/13/2021

  Total prescriptions of GOCOVRI of approximately 8,165 for fourth quarter 2020 and approximately 31,070* for full year 2020

• Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue

  1/13/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.

• Quanterix Provides Operational and Preliminary Financial Highlights

  1/13/2021

  Expects Q4 2020 GAAP revenue of $24-26 million; Non-GAAP revenue of $20-22 million, up approximately 32% over prior Q4 Quanterix to present at J.P. Morgan Healthcare Conference on January 13, 2021 at 3:40 pm ET